中重度银屑病患者换用阿达木单抗后的银屑病面积与严重程度指数应答:OPPSA研究结果
这项多中心研究纳入262例曾用抗TNF-α药物、乌司奴单抗或未用过生物制剂的银屑病患者,换用阿达木单抗后评估PASI应答。阿达木单抗使PASI从基线15.1±6.2降至6个月时2.7±4.8(P<0.0001),且不论既往生物制剂治疗如何。6个月时PASI 50、75、90应答率分别为92.5%、79%、56%,PASI 100应答率48.4%,并维持3年。
要点
- 阿达木单抗使PASI从基线15.1±6.2降至6个月时2.7±4.8(P<0.0001)。
- 6个月时PASI 50、75、90应答率分别为92.5%、79%、56%,PASI 100应答率48.4%。
- 应答维持3年,且不因既往使用生物制剂而不同。
核心结论
- 阿达木单抗在3年内有效降低PASI评分,不论患者既往未用过生物制剂还是曾用TNF-α或IL-12/23抑制剂。
研究设计与样本
- 多中心研究,纳入262例银屑病患者,既往接受抗TNF-α药物、乌司奴单抗或未用过生物制剂,后换用阿达木单抗。
- 在基线及第3、6、12、24、36个月评估PASI,并用逻辑回归分析临床危险因素与PASI应答的关联。
主要发现
- 阿达木单抗治疗使PASI从基线15.1±6.2降至6个月时2.7±4.8(P<0.0001),不论既往生物制剂治疗如何。
- 6个月时PASI 50、75、90应答率分别为92.5%、79%、56%,PASI 100应答率48.4%,并维持3年,不依赖既往生物制剂治疗。
- 无代谢综合征、无血脂异常、无高血压以及基线PASI较低和年龄较低与第3、6、12个月达到PASI应答相关。
- 在较晚时间点(第24和36个月),PASI 90和PASI 100应答与银屑病/银屑病关节炎诊断相关。
关键数值与推荐
- PASI 50、75、90应答率分别为92.5%、79%、56%,PASI 100应答率为48.4%(6个月时)。
- PASI从基线15.1±6.2降至6个月时2.7±4.8(P<0.0001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Few studies have compared the efficacy of switching to adalimumab in the real-life setting in plaque psoriasis patients. OBJECTIVE: To evaluate the effect of adalimumab in psoriasis patients previously treated with other biologics. METHODS: In this multicentre study, psoriasis patients (N = 262) treated with an anti-TNF-alpha agent, ustekinumab or naïve to biologics then switched to adalimumab were included. Disease severity was assessed by the Psoriasis Area and Severity Index (PASI) at baseline and after 3, 6, 12, 24 and 36 months. The association between clinical risk factors and achievement of PASI response was evaluated by logistic regression. RESULTS: Adalimumab treatment resulted in a decrease in PASI (15.1 ± 6.2 at baseline vs. 2.7 ± 4.8 at 6 months, P < 0.0001), regardless of previous biologic treatment. Furthermore, adalimumab allowed 92.5%, 79% and 56% of patients to achieve PASI response (PASI 50, 75 and 90, respectively) and complete remission (PASI 100 response) in 48.4% of patients, by 6 months and maintained over 3 years, independent of prior biologic treatment. The absence of metabolic syndrome, dyslipidemia, hypertension and lower PASI and lower age at baseline was associated with achievement of PASI response at 3, 6 and 12 months, whereas at later time points (24 and 36 months), PASI 90 and PASI 100 response was associated with diagnosis of psoriasis/psoriatic arthritis. CONCLUSION: Adalimumab was effective at reducing PASI score over 3 years, irrespective of whether patients were biologic naïve or previously treated with a TNF-alpha or IL-12/23 inhibitor.
引用
- Talamonti M, Galluzzo M, Bernardini N, et al. Psoriasis Area and Severity Index response in moderate-severe psoriatic patients switched to adalimumab: results from the OPPSA study. J Eur Acad Dermatol Venereol. 2018. PMID: 29776016. doi:10.1111/jdv.15077
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。